559 related articles for article (PubMed ID: 32610068)
1. Cancer Epigenetics, Tumor Immunity, and Immunotherapy.
Cao J; Yan Q
Trends Cancer; 2020 Jul; 6(7):580-592. PubMed ID: 32610068
[TBL] [Abstract][Full Text] [Related]
2. Epigenetics and immunotherapy: The current state of play.
Dunn J; Rao S
Mol Immunol; 2017 Jul; 87():227-239. PubMed ID: 28511092
[TBL] [Abstract][Full Text] [Related]
3. Epigenetics meets immune checkpoints.
Covre A; Coral S; Di Giacomo AM; Taverna P; Azab M; Maio M
Semin Oncol; 2015 Jun; 42(3):506-13. PubMed ID: 25965370
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
5. Surmounting cancer drug resistance: New insights from the perspective of N
Li B; Jiang J; Assaraf YG; Xiao H; Chen ZS; Huang C
Drug Resist Updat; 2020 Dec; 53():100720. PubMed ID: 32892147
[TBL] [Abstract][Full Text] [Related]
6. Anticancer potential of naturally occurring immunoepigenetic modulators: A promising avenue?
Schnekenburger M; Dicato M; Diederich MF
Cancer; 2019 May; 125(10):1612-1628. PubMed ID: 30840315
[TBL] [Abstract][Full Text] [Related]
7. Targeting the histone orthography of cancer: drugs for writers, erasers and readers.
Simó-Riudalbas L; Esteller M
Br J Pharmacol; 2015 Jun; 172(11):2716-32. PubMed ID: 25039449
[TBL] [Abstract][Full Text] [Related]
8. Is there a Role for Epigenetic Enhancement of Immunomodulatory Approaches to Cancer Treatment?
Flower KJ; Ghaem-Maghami S; Brown R
Curr Cancer Drug Targets; 2018; 18(1):5-15. PubMed ID: 28176650
[TBL] [Abstract][Full Text] [Related]
9. The emerging role of epigenetic therapeutics in immuno-oncology.
Topper MJ; Vaz M; Marrone KA; Brahmer JR; Baylin SB
Nat Rev Clin Oncol; 2020 Feb; 17(2):75-90. PubMed ID: 31548600
[TBL] [Abstract][Full Text] [Related]
10. Epigenetics in cancer: targeting chromatin modifications.
Ellis L; Atadja PW; Johnstone RW
Mol Cancer Ther; 2009 Jun; 8(6):1409-20. PubMed ID: 19509247
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic regulation of immune checkpoints: another target for cancer immunotherapy?
Ali MA; Matboli M; Tarek M; Reda M; Kamal KM; Nouh M; Ashry AM; El-Bab AF; Mesalam HA; Shafei AE; Abdel-Rahman O
Immunotherapy; 2017 Jan; 9(1):99-108. PubMed ID: 28000527
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors.
Perrier A; Didelot A; Laurent-Puig P; Blons H; Garinet S
Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32708698
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic Therapies and Potential Drugs for Treating Human Cancer.
Lin SQ; Li X
Curr Drug Targets; 2020; 21(11):1068-1083. PubMed ID: 32209040
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.
Mooradian MJ; Sullivan RJ
Future Oncol; 2017 Aug; 13(18):1649-1663. PubMed ID: 28776423
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic mechanisms of plant-derived anticancer drugs.
Schneider-Stock R; Ghantous A; Bajbouj K; Saikali M; Darwiche N
Front Biosci (Landmark Ed); 2012 Jan; 17(1):129-73. PubMed ID: 22201736
[TBL] [Abstract][Full Text] [Related]
16. Turning Cold into Hot: Firing up the Tumor Microenvironment.
Duan Q; Zhang H; Zheng J; Zhang L
Trends Cancer; 2020 Jul; 6(7):605-618. PubMed ID: 32610070
[TBL] [Abstract][Full Text] [Related]
17. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.
Fang DD; Tang Q; Kong Y; Wang Q; Gu J; Fang X; Zou P; Rong T; Wang J; Yang D; Zhai Y
J Immunother Cancer; 2019 Nov; 7(1):327. PubMed ID: 31779710
[TBL] [Abstract][Full Text] [Related]
18. Humanized Mice for the Study of Immuno-Oncology.
De La Rochere P; Guil-Luna S; Decaudin D; Azar G; Sidhu SS; Piaggio E
Trends Immunol; 2018 Sep; 39(9):748-763. PubMed ID: 30077656
[TBL] [Abstract][Full Text] [Related]
19. Natural compound-derived epigenetic regulators targeting epigenetic readers, writers and erasers.
Yang AY; Kim H; Li W; Kong AN
Curr Top Med Chem; 2016; 16(7):697-713. PubMed ID: 26306989
[TBL] [Abstract][Full Text] [Related]
20. An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer.
Burr ML; Sparbier CE; Chan KL; Chan YC; Kersbergen A; Lam EYN; Azidis-Yates E; Vassiliadis D; Bell CC; Gilan O; Jackson S; Tan L; Wong SQ; Hollizeck S; Michalak EM; Siddle HV; McCabe MT; Prinjha RK; Guerra GR; Solomon BJ; Sandhu S; Dawson SJ; Beavis PA; Tothill RW; Cullinane C; Lehner PJ; Sutherland KD; Dawson MA
Cancer Cell; 2019 Oct; 36(4):385-401.e8. PubMed ID: 31564637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
